Webinar: ACR/CHEST ILD Guidelines in Practice| Video: All the Lonely People

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: hip OA

Pediatric Care, Disparity Awareness Among Rheumatology Research Foundation-Funded Studies Underway

  |  

Investigators are tackling rheumatology practice challenges, assessing what drives career choices in pediatric rheumatology, improving fellowship training and more—all with the support of the Rheumatology Research Foundation.

ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis

  |  

ACR CONVERGENCE 2020—At the annual meeting’s second Plenary Session, Saturday, Nov. 7, speakers highlighted phase 2 results of a potential new biologic for systemic lupus erythematosus (SLE), as well as data on remission maintenance in rheumatoid arthritis (RA) after withdrawal of etanercept or methotrexate. Phase 2 Trial of Monoclonal Antibody for Lupus (LILAC) Several converging…

ACR Convergence 2020: COVID-19 Hyper-Inflammation in Kids

  |  

ACR CONVERGENCE 2020—Among the many ways in which the COVID-19 pandemic has changed the face of modern medicine is the emergence of multisystem inflammatory syndrome in children (MIS-C), a rare but serious condition that shares many features of Kawasaki disease (KD). With this topic in mind, leading pediatric experts from around the world came together…

Under Pressure: An Update on Pulmonary Hypertension

  |  

ACR CONVERGENCE 2020—In patients with connective tissue diseases, such as systemic sclerosis (SSc), pulmonary hypertension (PH) remains one of the leading causes of morbidity and mortality. In her lecture on Friday, Nov. 6, Pulmonary Hypertension: An Update, Mardi Gomberg-Maitland, MD, MSc, professor of medicine and medical director of the Pulmonary Hypertension Program at The George…

The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?

  |  

ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…

ACR Convergence 2020: Studies in Rheumatoid Arthritis

  |  

ACR CONVERGENCE 2020—Moderated by Bill St.Clair, MD, MACR, an ACR past president and a professor of medicine and immunology at Duke University Medical Center, Durham, N.C., an abstract session on Friday, Nov. 6, focused on the diagnosis, manifestations and outcomes of rheumatoid arthritis (RA), with a focus on interstitial lung disease. RA with ILD Jeffrey…

Incoming ACR President David Karp, MD, PhD, Eager to Move Forward on Workforce Shortage, Workplace Bias & Member Engagement

  |  

With extensive leadership experience in practice and through many roles with the ACR’s committees, executive board of directors and Rheumatology Research Foundation, Dr. Karp is ready to address workforce shortages, workplace bias and member engagement to ensure a strong future for the College through COVID-19 and beyond.